DARIFENACIN: FDA Approved Drugs and User Comments
' + "
";
evCat = 'adx-impl';
evLabel = '/21865806531/yl-xk/336*280-01-wap-xk-yl';
} else {
html = "
" + '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/728*90-01-pc-xk-yl", [728, 90], "div-gpt-ad-1576640512222-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640512222-0")});
' + "
";
evCat = 'adx-impl';
evLabel = '/21865806531/yl-xk/728*90-01-pc-xk-yl';
}
var html2 = replaceAll2(html, "script2", "script");
fillHtml += randomAdxSlotId(html2);
_pf_event(evCat, PAGE_CAT, evLabel);
_pf_log("ga adsense single");
}
document.write(fillHtml);
}
showAd();
})();
Drug Name |
Active Ingredients |
Strength |
Dosage Form/Route |
Marketing Status |
DARIFENACIN |
DARIFENACIN HYDROBROMIDE |
EQ 7.5MG BASE |
TABLET, EXTENDED RELEASE;ORAL |
Prescription |
DARIFENACIN |
DARIFENACIN HYDROBROMIDE |
EQ 15MG BASE |
TABLET, EXTENDED RELEASE;ORAL |
Prescription |
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
";
}
function showAd(){
var s = getQueryStringByName('s');
var isSearchPage = (s != '');
var isMobile = /iPhone|iPad|iPod|Android/i.test(navigator.userAgent);
var html = '';
var html2 = '';
if (isSearchPage) {
if (isMobile) {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-01-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640284306-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640284306-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-01-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-02-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640310637-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640310637-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-02-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-03-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640337768-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640337768-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-03-wap-n-xk-yl');
} else {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-pc-n-xk-yl", [300, 600], "div-gpt-ad-1576640117816-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640117816-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-pc-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-02-pc-n-xk-yl", [300, 600], "div-gpt-ad-1576640172416-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640172416-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-02-pc-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl", [300, 600], "div-gpt-ad-1576639775063-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639775063-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl');
}
} else {
if (isMobile) {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-04-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640363074-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640363074-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-04-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-05-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640388002-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640388002-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-05-wap-n-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/336x280-06-wap-n-xk-yl", [336, 280], "div-gpt-ad-1576640412938-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576640412938-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/336x280-06-wap-n-xk-yl');
} else {
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl", [300, 600], "div-gpt-ad-1576639775063-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639775063-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x250-01-healthtopquestions-xk-yl", [300, 250], "div-gpt-ad-1576639270555-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639270555-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x250-01-healthtopquestions-xk-yl');
html2 = '
googletag.cmd.push(function() {googletag.defineSlot("/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl", [300, 600], "div-gpt-ad-1576639775063-0").addService(googletag.pubads());googletag.pubads().enableSingleRequest();googletag.enableServices()});googletag.cmd.push(function() {googletag.display("div-gpt-ad-1576639775063-0")});
'; html2 = randomAdxSlotId(html2);
html += html2;
_pf_event('adx-impl', PAGE_CAT, '/21865806531/yl-xk/300x600-01-healthtopquestions-xk-yl');
}
}
var html2 = replaceAll2(html, 'script2', 'script');
document.write(html2);
}
showAd();
})();
User Comments:
Enablex (darifenacin) for Overactive Bladder: “I am on day 3 of 15mg of enablex and my symptoms have gotten worse. due to the dry mouth I am drinking more which is making me go to.the bathroom more than I already was. Did anyone else have this problem??”
34 female canada (taken for less than 1 month) December 7, 2016
Enablex (darifenacin) for Overactive Bladder: “I was on vesicare for over a year and didn’t feel much relief. When my Doctor changed me to Enablex I got immediate results without the annoying dry mouth symptoms. Been on this medication for 2 years and I love it!”
Tricky lady December 28, 2015
Enablex (darifenacin) for Overactive Bladder: “Worked fine from day one. Stopped the urge for frequent trips to the bathroom. I have not had any symptoms of side effects such as swelling of feet or legs etc, Been taking daily 7.5mg. Only complaint is the very expensive cost.”
chirashi123 (taken for less than 1 month) July 31, 2013
Enablex (darifenacin) for Overactive Bladder: “Took this medication for three months. It made me burn and raw, even alternating it to three times a week. Directions said not to cut, so I couldn’t back down more. It seems the medication worked as far as the bladder symptoms but was unusable for me on a long term basis.”
Laura Powell (taken for 1 to 6 months) June 11, 2013
Enablex (darifenacin) for Urinary Incontinence: “Constipation, dizziness, hallucinations while sleeping.”
blum May 15, 2013
Enablex (darifenacin) for Urinary Incontinence: “My father-in-law took this medication and it gave him alot of extra pyramidal movements and Tardive Dyskinesia.”
Nurseninja (taken for less than 1 month) March 6, 2013